Seagen looks set to sustain double-digit growth in 2023 as its antibody-drug conjugates (ADCs) expand into first-line uses, led by the lymphoma treatment Adcetris and urothelial cancer therapy, Padcev.
ADCs, which harness antibodies to deliver targeted cytotoxic payloads to tumors, have become one of the fastest-growing classes in oncology,...








